{"product_id":"guerbet-business-model-canvas","title":"Guerbet Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuerbet Business Model Canvas: Strategic Blueprint for Value, Market Share \u0026amp; Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Guerbet’s business model—this in-depth Business Model Canvas shows how the company creates value, captures market share, and sustains competitive advantage; ideal for investors, consultants, and founders seeking actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic AI Technology Collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuerbet partners with AI developers to embed advanced algorithms into imaging suites, automating liver and prostate lesion detection and improving diagnostic sensitivity by up to 18% in pilot studies; these deals contributed to a 2024–2025 digital revenue uptick of ~12%, and by end-2025 are cited as essential for retaining market share in digital health.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGroup Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with large Group Purchasing Organizations (GPOs) let Guerbet secure multi-year supply contracts with hospital networks covering roughly 40–50% of US hospital purchases; GPO-negotiated volume and price commitments supported about €310m in contrast-agent sales in 2024, ensuring steady CT\/MRI supply and protecting share in competitive imaging markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn markets where Guerbet lacks direct presence, specialized local distributors with deep regulatory expertise handle cold-chain logistics, local storage, and last-mile delivery for temperature-sensitive contrast agents, cutting import delays by up to 30% in pilot countries in 2024. This distributor network supports Guerbet’s reach in over 80 countries by 2025, generating roughly 40% of emerging-market revenues (≈€120m in 2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJoint ventures with top universities and research hospitals supply Guerbet with clinical trials and real-world data needed for regulatory approvals; a 2024 phase II alliance with Karolinska and AP-HP aimed to recruit 300 patients and cut IND timelines by ~20%.\u003c\/p\u003e\n\u003cp\u003eThese partners generate peer-reviewed papers—Guerbet-backed studies yielded 12 publications in 2023—boosting brand authority and supporting early-stage development of molecular imaging tracers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e300-patient 2024 trial goal\u003c\/li\u003e\n\u003cli\u003e~20% IND timeline reduction\u003c\/li\u003e\n\u003cli\u003e12 peer-reviewed papers in 2023\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eReliable long-term agreements with iodine and gadolinium miners secure 95% of Guerbet’s feedstock needs, cutting production downtime risk amid 20–30% price swings in rare chemical markets.\u003c\/p\u003e\n\u003cp\u003eBy Q4 2025 Guerbet expanded to 6 strategic suppliers across Europe and Asia, lowering single-country sourcing exposure from 78% to 42% and reducing geopolitical supply-risk score by 55%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e95% feedstock coverage\u003c\/li\u003e\n\u003cli\u003e20–30% market volatility\u003c\/li\u003e\n\u003cli\u003e6 suppliers by late 2025\u003c\/li\u003e\n\u003cli\u003eExposure down 78%→42%\u003c\/li\u003e\n\u003cli\u003eRisk score −55%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuerbet partners fuel 12% digital growth, €430M+ sales \u0026amp; 95% feedstock coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuerbet’s key partners—AI vendors, GPOs, local distributors, research hospitals, and feedstock miners—drove a 12% digital revenue rise (2024–25), secured ~€310m contrast sales via GPOs in 2024, enabled 80+ country reach generating ≈€120m EM revenue (2024), supported a 300-patient 2024 trial (−20% IND time), and covered 95% feedstock needs with 6 suppliers by Q4 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003e2024–25 KPI\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI vendors\u003c\/td\u003e\n\u003ctd\u003eDigital rev uplift\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPOs\u003c\/td\u003e\n\u003ctd\u003eContrast sales\u003c\/td\u003e\n\u003ctd\u003e≈€310m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003eEM revenue\u003c\/td\u003e\n\u003ctd\u003e≈€120m (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch hospitals\u003c\/td\u003e\n\u003ctd\u003eTrial size \/ IND\u003c\/td\u003e\n\u003ctd\u003e300 pts \/ −20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMiners\u003c\/td\u003e\n\u003ctd\u003eFeedstock coverage\u003c\/td\u003e\n\u003ctd\u003e95% (6 suppliers)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Guerbet detailing its nine BMC blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure—aligned with real-world radiology contrast agent operations and strategic plans to support presentations, investor discussions, and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Guerbet’s business model with editable cells, letting teams quickly map its contrast agents, regulatory pathways, and distribution channels to relieve strategic uncertainty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContrast Media Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuerbet R\u0026amp;D focuses on next‑gen contrast agents that raise efficacy while cutting dose; current programs aim for 20–40% dose reduction vs older agents and a 30% lower nephrotoxicity signal in preclinical studies (2024 data). Ongoing pipeline investment was €68M in 2024, keeping 5 clinical candidates aligned with evolving MRI\/CT clinical needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndustrial Pharmaceutical Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuerbet runs multiple high‑tech plants for chemical synthesis and aseptic filling that follow strict Good Manufacturing Practices (GMP) to guarantee vial purity and safety; in 2024 these facilities produced over 120 million doses with a batch-release compliance rate above 99.5%. By 2025 the company completed a €90 million automation upgrade program, raising yields by ~12% and cutting solvent use and CO2 emissions per unit by 18%, lowering manufacturing costs and environmental impact.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health Solution Engineering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuerbet builds software platforms for radiologists, combining data engineering, ML model training, and UI design to speed image interpretation and manage workflows; in 2025 R\u0026amp;D digital investments rose ~22% y\/y to €48M, targeting a 15% reduction in reading time per case. Integration with PACS\/HIS (DICOM\/HL7\/FHIR) and APIs is a core task to ensure 99% uptime and seamless hospital deployment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Marketing and Medical Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMarketing leads high-level scientific communication to inform HCPs about Guerbet imaging solutions, running ~120 webinars in 2024 and sponsoring \u0026gt;40 major congresses (including RSNA 2024), plus hands-on injection-system training that reached ~3,500 clinicians globally.\u003c\/p\u003e\n\u003cp\u003ePriority: educate on clinical value of interventional oncology devices—sales of specialized IO products rose 18% in FY 2024, driving targeted market uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~120 webinars in 2024\u003c\/li\u003e\n\u003cli\u003eSponsored \u0026gt;40 congresses (RSNA 2024)\u003c\/li\u003e\n\u003cli\u003e3,500 clinicians trained\u003c\/li\u003e\n\u003cli\u003eIO product sales +18% in FY 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Quality Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpguerbet regulatory affairs and quality compliance teams continually secure maintain market access by pursuing fda ema approvals spent on r filings in ensuring portfolio across markets pharmacovigilance monitors\u003e120k post-market examinations and reports adverse events to regulators within required timelines. \n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e€45m regulatory\/R\u0026amp;D spend (2024)\u003c\/li\u003e\n\u003cli\u003eFDA and EMA approval pipelines active\u003c\/li\u003e\n\u003cli\u003ePharmacovigilance: ~120,000 post-market checks\u003c\/li\u003e\n\u003cli\u003eTimely adverse-event reporting to regulators\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pguerbet\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuerbet scales safer, lower‑dose contrast solutions: €206M R\u0026amp;D \u0026amp; capex, 120M doses, \u0026gt;99.5% compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuerbet runs R\u0026amp;D, GMP manufacturing, digital platforms, marketing\/training, and regulatory\/QC to deliver lower‑dose, safer contrast agents and imaging software; 2024–25 figures: €68M pipeline R\u0026amp;D, €48M digital R\u0026amp;D (2025), €90M automation capex, 120M doses produced (2024), \u0026gt;99.5% batch compliance, 3,500 clinicians trained, IO sales +18%, ~€45M regulatory spend, ~120k pharmacovigilance checks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline R\u0026amp;D (2024)\u003c\/td\u003e\n\u003ctd\u003e€68M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital R\u0026amp;D (2025)\u003c\/td\u003e\n\u003ctd\u003e€48M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAutomation capex\u003c\/td\u003e\n\u003ctd\u003e€90M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoses produced (2024)\u003c\/td\u003e\n\u003ctd\u003e120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch compliance\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;99.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians trained (2024)\u003c\/td\u003e\n\u003ctd\u003e3,500\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIO sales growth (FY2024)\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\/R\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003ctd\u003e€45M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacovigilance checks\u003c\/td\u003e\n\u003ctd\u003e~120,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the exact Guerbet Business Model Canvas you’ll receive after purchase—not a mockup or sample. When you complete your order, you’ll instantly get this same professional, fully editable file in Word and Excel formats. No hidden content or altered layouts—what you see is the complete, ready-to-use deliverable for presentation, editing, or sharing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749519438201,"sku":"guerbet-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/guerbet-business-model-canvas.png?v=1772214677","url":"https:\/\/growthsharematrix.com\/products\/guerbet-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}